ResMed (RMD): Sleep-Health Growth With Margin Upside
ResMed combines durable sleep-apnea demand, connected digital health, and expanding margins. The report supports a Buy view despite valuation discipline and product-transition risks.
ResMed combines durable sleep-apnea demand, connected digital health, and expanding margins. The report supports a Buy view despite valuation discipline and product-transition risks.

ResMed Inc. (RMD) merits a Buy rating for moderate-risk investors with a medium-term horizon. The investment case rests on a durable sleep and breathing franchise, a connected digital-health ecosystem, strong cash generation, and margin expansion that can support earnings growth above revenue growth.
The latest quoted price in the assembled market snapshot was $253.43, against trailing and forward P/E ratios of 21.8x and 20.0x. ResMed reported fiscal Q1 2027 revenue of approximately $1.4B, up 6% year over year on a reported basis, while non-GAAP EPS rose 14% to $2.91. Management reaffirmed full-year revenue guidance of $5.75B to $5.85B and non-GAAP EPS guidance of $12.00 to $12.25.
The strongest part of the thesis is the combination of growth and quality. Fiscal 2026 revenue reached $5.65B, operating margin reached 33.8%, free cash flow reached $1.65B, and earnings grew 23.2% year over year in the latest core valuation data. ResMed also has $1.47B of cash against $688.5M of fiscal 2026 debt in the annual balance-sheet data.
The principal risks are valuation discipline, inflation in electronic components, a planned Astral life-support device exit, the eventual competitive response from Philips, and the possibility that alternative therapies alter sleep-apnea treatment patterns. Those risks temper the upside case, but the 8-for-8 earnings beat record, a 5.8% free-cash-flow yield, and management's reaffirmed outlook support a constructive stance.
ResMed is a global health-technology company founded in 1989 and headquartered in San Diego. It employs approximately 11,370 people and sells products in more than 140 countries. Michael Farrell serves as CEO and chairman, while Aaron Bloomer serves as CFO.
ResMed's business model combines medical hardware with software and recurring replacement demand. A patient can begin with a diagnostic product, move to an AirSense or AirCurve device, use a mask and accessories, and remain connected through myAir and AirView. That structure gives ResMed several points of contact across the therapy journey.
The 2026 10-K describes the MatrixCare sale as portfolio optimization focused on sleep, breathing, and connected home-based healthcare. The transaction closed on September 1, 2026, and management expects the remaining Residential Care Software business to deliver high-single-digit revenue growth with operating leverage in fiscal 2027.
Sleep and Breathing Health is the economic center of ResMed. Fiscal 2026 segment revenue reached $4.98B, up 10% from fiscal 2025 according to the company's reported segment data. In fiscal Q1 2027, the segment generated $1.26B and grew 8% year over year in core constant currency terms.
Within the product portfolio, devices represented approximately 51% of fiscal 2026 revenue, while masks and other products represented approximately 37%. The mix matters because masks and accessories add a replacement component to a device-led business and can support higher-margin growth.
Fiscal Q1 2027 showed healthy demand across the core portfolio. Americas sleep-device revenue increased 6%, Americas masks and other revenue increased 10%, and Rest of World masks and other revenue increased 11% in the earnings discussion. Rest of World sleep-device demand also benefited from a fleet refresh in France, creating a favorable first-half comparison and a second-half normalization risk.
Residential Care Software revenue increased 5% in constant currency during fiscal Q1 2027. Excluding MatrixCare, Brightree and MEDIFOX DAN grew 8%. The divestiture reduces reported revenue, but it also makes the remaining software portfolio more closely aligned with ResMed's home-care strategy.
The main segment issue is the Astral decision. ResMed will no longer sell the Astral life-support device and expects the move to create an approximately $75M revenue headwind, or 130 basis points of fiscal 2027 core constant-currency growth. Management's guidance excludes that product from future growth ambitions, which makes the underlying sleep and mask trends more important.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
AirSense 11 is ResMed's flagship connected CPAP and APAP platform. It combines therapy delivery, a built-in humidifier, touchscreen controls, remote software updates, and integration with myAir. The platform gives ResMed a broad installed base from which to introduce new software features and replacement accessories.
AirCurve 11 extends the same platform into bilevel therapy for patients requiring greater pressure support or treatment for complex sleep apnea, central sleep apnea, and COPD with obstructive sleep apnea. The platform approach lets ResMed reuse technology and digital workflows across a wider group of patients.
The AirTouch F40 fabric mask adds a product-level adherence argument. ResMed reported that 91% of patients in its study rated the mask comfortable or very comfortable at initial fitting. The company also reported a 6% increase in therapy adherence for its newer fabric masks versus silicone equivalents.
The product economics improve when comfort drives adherence and adherence drives resupply. The myAir Equipment Care feature reminds patients when masks and accessories are eligible for replacement, creating a practical link between digital engagement and recurring product demand.
ResMed's competitive advantage is a system rather than a single device. The company combines masks, devices, diagnostics, cloud connectivity, patient applications, provider monitoring, and clinical education. That system can reduce friction for patients while helping providers manage more therapy users.
The scale of the data ecosystem is significant. Management reported more than 13 million myAir downloads, more than 2.1 million inquiries to the Dawn generative-AI sleep coach, and more than 35 million patients using cloud-connected devices on AirView in the company's 10-K strategy discussion.
Smart Comfort is another example of data being converted into a product feature. The FDA-cleared tool uses ResMed sleep data to recommend comfort settings such as temperature, humidity, ramp time, and pressure relief. Early real-world data showed a 4.3% increase in 30-day compliance versus default settings.
The ecosystem also reaches outside the traditional medical-device channel. The OURA relationship generated approximately 28,000 visits to ResMed.com by September 30, and approximately 72% of assessed users identified themselves as previously undiagnosed for obstructive sleep apnea. The Eight Sleep partnership adds another consumer sleep-data pathway.
The moat is reinforced by clinical workflow integration. ResMed's sleep-apnea education courses were completed approximately 108,000 times by more than 63,000 unique clinicians. In a category where patient comfort and therapy continuity matter, physician familiarity and provider workflow fit can be as important as a modest hardware specification advantage.
ResMed operates manufacturing and distribution facilities across Australia, the United States, Singapore, and Malaysia. The company produced its first U.S.-made AirSense 11 device at its Atlanta facility and is building a distribution center in Indianapolis to improve delivery speed to North American customers.
Management said supply-chain productivity across procurement, manufacturing, and distribution helped fiscal Q1 2027 non-GAAP gross margin reach 62.5%, up 50 basis points year over year. The timing of Indiana expansion spending also helped the quarter's margin performance.
The operational risk is inflation in electronic components. CFO Aaron Bloomer said those pressures are expected to build through the remainder of fiscal 2027. ResMed is relying on productivity, product mix, pricing, and facility efficiency to offset that pressure.
The global footprint provides flexibility, but it also creates exposure to foreign exchange, tariffs, transportation costs, and regional disruption. Domestic U.S. production and the Singapore and Malaysia expansion give ResMed more options than a single-site model, without eliminating the complexity of global manufacturing.
ResMed operates in a large and underpenetrated sleep-apnea market. Company materials cite an estimated 936 million people globally with obstructive sleep apnea, while diagnosis or treatment penetration is below 20% in the United States and below 10% in other markets.
The company estimates that global device demand is growing at a mid-single-digit rate and the mask market is growing at a high-single-digit rate. Those figures fit ResMed's current outlook, which calls for 5% to 7% fiscal 2027 core constant-currency revenue growth despite the Astral headwind.
Demand creation is becoming more important than simple replacement cycles. Wearables, smart mattresses, GLP-1 prescriptions, physician education, and consumer marketing can bring undiagnosed patients into the screening process. ResMed reported that patients with both CPAP and GLP-1 prescriptions were more than 11% more likely to start CPAP therapy than patients with a CPAP prescription alone.
The market's long-term attraction is paired with a practical constraint: diagnosis, reimbursement, patient adherence, and provider capacity all influence conversion from prevalence to revenue. ResMed's digital tools address adherence and provider capacity, while its OURA and Eight Sleep relationships address the awareness and screening pathway.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
ResMed serves several connected customer groups. Patients use devices, masks, accessories, and applications. Sleep physicians and other clinicians prescribe and monitor therapy. Home medical equipment providers distribute products and manage resupply. Payers influence reimbursement and treatment access.
The patient relationship is central because CPAP is a continuing therapy rather than a one-time intervention. Management said myAir and AirView can improve therapy compliance from 70% to 87% when myAir is added for the patient. Smart Comfort's reported 4.3% improvement in 30-day compliance adds another data point supporting the value of personalization.
Provider customers value efficient workflows and lower service costs. Dawn is designed to answer routine patient questions and reduce customer-service inquiries for ResMed and its HME partners. Equipment Care also helps providers identify resupply opportunities without relying entirely on manual outreach.
The Residential Care Software customer base includes HME and home-infusion providers, skilled-nursing facilities, senior-living operators, and other residential-care organizations. ResMed's 10-K says its software solutions support providers serving more than 180 million individual patient accounts, although the MatrixCare divestiture narrows the portfolio around the remaining core businesses.
ResMed's 2026 10-K identifies Philips, Fisher & Paykel Healthcare, DeVilbiss Healthcare, Apex Medical, BMC Medical, React Health, Jiangsu Yuyue Medical Equipment & Supply, and Löwenstein Medical as competitors in sleep and breathing health.
ResMed's edge is the breadth of its connected platform. It competes across devices, masks, diagnostics, ventilation, remote monitoring, and patient engagement rather than relying on one hardware category. Fiscal Q1 2027 gross margin of 62.5% and operating margin of 35.8% show that the platform currently supports substantial profitability.
Philips remains the most important strategic variable. The 10-K says Philips' recall-related restrictions created an opportunity for competitors, while Philips' eventual return to normal flow-generator sales could change market dynamics. That risk argues against assigning ResMed an unlimited premium.
Competition also comes from outside medical devices. ResMed identifies dental appliances, surgery, nerve-stimulation devices, and pharmaceutical treatments as alternative approaches to obstructive sleep apnea. GLP-1 medicines can expand diagnosis and treatment in the near term, but their long-term effect on obesity-related sleep apnea remains a strategic variable.
ResMed's macro exposure is visible in its fiscal 2027 guidance. The company assumes a 60-basis-point foreign-exchange headwind based on quarter-end rates, continued inflation pressure on customers, and a second-half slowdown in Rest of World sleep devices after the French fleet refresh concludes.
The company is also exposed to global trade and manufacturing policy because it sells in more than 140 countries and operates facilities across multiple regions. Management is advocating for policies that support domestic U.S. manufacturing and supply-chain resilience while expanding U.S. production.
Healthcare regulation is another macro force. ResMed's products require regulatory clearances and operate within reimbursement systems. The Astral field safety corrective action illustrates how quality and regulatory issues can affect revenue, inventory allocation, customer planning, and brand trust at the same time.
The offset is the shift toward home-based care. ResMed's devices and software align with care models that reduce hospital dependence and allow providers to monitor patients remotely. That structural shift supports the company's strategy even when currency and component costs move against it.
ResMed holds $1.47B in cash against $688.5M of fiscal 2026 debt, giving it a net cash position that supports flexibility even as it exits Astral.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Fiscal 2026 revenue reached $5.65B and operating margin hit 33.8%, while free cash flow climbed to $1.65B and earnings grew 23.2% year over year.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management reaffirmed fiscal 2027 revenue guidance of $5.75B to $5.85B and non-GAAP EPS guidance of $12.00 to $12.25, despite a planned $75M Astral headwind.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At 21.8x trailing earnings and 20.0x forward earnings, ResMed trades at a premium that is partly justified by a 5.8% free-cash-flow yield and 8-for-8 earnings beats.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report's fair value is $265.11, above the latest quoted price of $253.43 and consistent with a Buy view for moderate-risk investors.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →ResMed is a high-quality medical-device and digital-health company with a durable category position. Its fiscal 2026 results show revenue of $5.65B, operating margin of 33.8%, net income of $1.52B, and free cash flow of $1.65B. Fiscal Q1 2027 added another 14% increase in non-GAAP EPS and 50 basis points of gross-margin expansion.
The next phase depends on execution rather than a rescue event. ResMed must convert AirTouch and AirCurve innovation into adoption, maintain productivity through 2030, expand digital engagement, manage the Astral transition, and protect margins against component inflation. The business has the balance sheet and installed ecosystem to pursue those goals.
At the latest quoted price of $253.43, the shares offer moderate upside to the report's fair value estimate of $265.11, not a dramatic bargain. That profile fits a Buy rating for investors who value consistent earnings, strong cash flow, and exposure to the long-term shift toward connected care in the home.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime

ResMed Inc. (RMD) falls after hours as investors react to a softer fiscal 2027 outlook tied to suspended ventilator sales and higher cost pressure. The company still topped Q4 EPS estimates and posted solid full-year revenue growth, but guidance concerns are driving the selloff.

The $490 million MatrixCare sale and planned ASR improve capital-return optics, but they do not answer the FY2027 growth question. With a 60/100 Growth component in the TickerSpark Score and a 20.30 P/E, RMD remains a defensive setup before the next proof point.

ResMed pairs double-digit revenue growth, strong margins, and net cash with a large underpenetrated sleep-apnea market. The stock remains a Buy, but valuation and an Astral field-action headwind temper upside.